Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma Meeting Abstract
| Authors: | Al-Batran, S. E.; Wainberg, Z. A.; Muro, K.; Molena, D.; Van Cutsem, E.; Hyung, W. J.; Wyrwicz, L. S.; Moehler, M.; Herrero, F. R.; Oh, D. Y.; Omori, T.; Smyth, E. C.; Liberman, M.; Stein, A.; Bilici, M.; Serrano, O.; Heilbron, E.; Hernandorena, F.; Tabernero, J.; Janjigian, Y. Y. |
| Abstract Title: | Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma |
| Meeting Title: | ESMO Gastrointestinal Cancers Congress Congress 2025 |
| Journal Title: | Annals of Oncology |
| Volume: | 36 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2025 Jul 2-5 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2025-07-01 |
| Start Page: | S150 |
| End Page: | S151 |
| Language: | English |
| ACCESSION: | WOS:001545624000058 |
| DOI: | 10.1016/j.annonc.2025.05.544 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA4 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
